Slow enrollment in the phase-2a trial. This was recently addressed by relaxing the restrictions on patient eligibility in an undisclosed way. (We could probably figure out the change with a modicum of DD.) The salient point is that the phase-2a data in stable angina must be mature before MNTA can partner the program.
>Did they happen to mention the oncology candidate?<
No. This was a much shorter quarterly CC than usual because there was a long CC (on the Copaxone filing) only two weeks ago. Moreover, Wheeler used several minutes at the outset to rebut the erroneous comments some analysts and writers have been making about the Copaxone ANDA. This, alone, was worth the price of admission.
All told, I thought this was another very good CC with the exception of the slippage in the M118 timeline.
Let’s talk biotech! “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Market Data 
Markets 
AI
